Literature DB >> 29452567

A critical role for both CD40 and VLA5 in angiotensin II-mediated thrombosis and inflammation.

Elena Y Senchenkova1,2, Janice Russell1, Shantel A Vital1, Alper Yildirim1,3, A Wayne Orr4, D Neil Granger1, Felicity N E Gavins1,5.   

Abstract

Angiotensin II (Ang-II)-induced hypertension is associated with accelerated thrombus formation in arterioles and leukocyte recruitment in venules. The mechanisms that underlie the prothrombotic and proinflammatory responses to chronic Ang-II administration remain poorly understood. We evaluated the role of CD40/CD40 ligand (CD40L) signaling in Ang-II-mediated microvascular responses and assessed whether and how soluble CD40L (sCD40L) contributes to this response. Intravital video microscopy was performed to analyze leukocyte recruitment and dihydrorhodamine-123 oxidation in postcapillary venules. Thrombus formation in cremaster muscle arterioles was induced by using the light/dye endothelial cell injury model. Wild-type (WT), CD40-/-, and CD40L-/- mice received Ang-II for 14 d via osmotic minipumps. Some mice were treated with either recombinant sCD40L or the VLA5 (very late antigen 5; α5β1) antagonist, ATN-161. Our results demonstrate that CD40-/-, CD40L-/-, and WT mice that were treated with ATN-161 were protected against the thrombotic and inflammatory effects of Ang-II infusion. Infusion of sCD40L into CD40-/- or CD40L-/- mice restored the prothrombotic effect of Ang-II infusion. Mice that were treated with ATN-161 and infused with sCD40L were protected against accelerated thrombosis. Collectively, these novel findings suggest that the mechanisms that underlie Ang-II-dependent thrombotic and inflammatory responses link to the signaling of CD40L via both CD40 and VLA5.-Senchenkova, E. Y., Russell, J., Vital, S. A., Yildirim, A., Orr, A. W., Granger, D. N., Gavins, F. N. E. A critical role for both CD40 and VLA5 in angiotensin II-mediated thrombosis and inflammation.

Entities:  

Keywords:  endothelium; hypertension; leukocytes; platelets; sCD40L thrombosis

Mesh:

Substances:

Year:  2018        PMID: 29452567     DOI: 10.1096/fj.201701068R

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  7 in total

1.  Targeting of Formyl Peptide Receptor 2 for in vivo imaging of acute vascular inflammation.

Authors:  Tamara Boltersdorf; Junaid Ansari; Elena Y Senchenkova; Jieny Groeper; Denise Pajonczyk; Shantel A Vital; Gaganpreet Kaur; J Steve Alexander; Thomas Vogl; Ursula Rescher; Nicholas J Long; Felicity N E Gavins
Journal:  Theranostics       Date:  2020-05-17       Impact factor: 11.556

2.  Novel Role of T Cells and IL-6 (Interleukin-6) in Angiotensin II-Induced Microvascular Dysfunction.

Authors:  Elena Y Senchenkova; Janice Russell; Alper Yildirim; D Neil Granger; Felicity N E Gavins
Journal:  Hypertension       Date:  2019-04       Impact factor: 10.190

3.  The mechanism by which enoxaparin sodium-high-viscosity bone cement reduces thrombosis by regulating CD40 expression in endothelial cells.

Authors:  Linchao Sang; Kangning Hao; Luobin Ding; Xiaoyu Shen; Hui Sun; Dehao Fu; Xiangbei Qi
Journal:  BMC Musculoskelet Disord       Date:  2022-05-30       Impact factor: 2.562

4.  Angiotensin II in ECMO patients: a word of caution.

Authors:  Elio Antonucci; Fabio Silvio Taccone
Journal:  Crit Care       Date:  2019-04-26       Impact factor: 9.097

Review 5.  Revisiting Pleiotropic Effects of Type I Interferons: Rationale for Its Prophylactic and Therapeutic Use Against SARS-CoV-2.

Authors:  Diana Garcia-Del-Barco; Daniela Risco-Acevedo; Jorge Berlanga-Acosta; Frank Daniel Martos-Benítez; Gerardo Guillén-Nieto
Journal:  Front Immunol       Date:  2021-03-26       Impact factor: 7.561

6.  Why the Use of Angiotensin II May be a Fatal Mistake in COVID-19.

Authors:  Jason A Ferreira; Jessica Mcmanus; Christopher A Jankowski; Randi Searcy
Journal:  Shock       Date:  2020-11       Impact factor: 3.533

Review 7.  The vascular nature of COVID-19.

Authors:  Matthijs Oudkerk; Dirkjan Kuijpers; Sytse F Oudkerk; Edwin Jr van Beek
Journal:  Br J Radiol       Date:  2020-07-31       Impact factor: 3.039

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.